A phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme

Journal of Neurosurgery

Volumn 113, Issue 2, 2010, Pages 192-198

  Li, Linna ^a   Quang, Tony S ^b   Gracely, Ed J ^c   Kim, Ji H ^d   Emrich, Jacqueline G ^c   Yaeger, Theodore E ^e   Jenrette, Joseph M ^f   Cohen, Steven C ^g   Black, Perry ^c   Brady, Luther W ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d Wake Forest University School of Medicine ^*  (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g BRYN MAWR HOSPITAL   (United States)

Author keywords

125iodine labeled monoclonal antibody 425; Anti epidermal growth factor receptor; Glioblastoma multiforme; Radioimmunotherapy; Temozolomide

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IODINE 125; MONOCLONAL ANTIBODY 425; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; GLIOBLASTOMA; HUMAN; HYPOTENSION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SIDE EFFECT; SKIN IRRITATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; IODINE RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOIMMUNOTHERAPY; RADIOTHERAPY, ADJUVANT; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 77955633497     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2010.2.JNS091211     Document Type: Article

References (54)

1. American Cancer Society: Estimated New Cancer Cases and Deaths by Sex for All Sites, US, 2007. Cancer Facts & Figures 2007. (http://www.cancer.org/ docroot/MED/content/ downloads/MED-1-1x-CFF2007-Estimated-New-Cases- Deaths-by-Sex-US.asp) [Accessed March 1, 2010]
2. Aoki T, Takahashi JA, Ueba T, Oya N, Hiraoka M, Matsui K, et al: Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. J Neurosurg 105:385-391, 2006 (Pubitemid 44358745)
3. Barnholtz-Sloan JS, Sloan AE, Schwartz AG: Cancer of the brain and other central nervous system, in Gloeckler Ries LA, Young JL Jr, Keel GE, et al (eds): SEER Survival Monograph. Cancer Survival Among Adults: U.S. SEER Program, 1988-2001. Patient and Tumor Characteristics. Bethesda: National Cancer Institute, SEER Program, 2007, pp 203-216
4. Bender H, Emrich JG, Eshelman J, Chu MA, Steplewski Z, Biersack HJ, et al: External beam radiation enhances antibody mediated radiocytotoxicity in human glioma cells in vitro. Anticancer Res 17 (3B):1797-1802, 1997 (Pubitemid 27263163)
5. Bender H, Takahashi H, Adachi K, Belser P, Liang SH, Prewett M, et al: Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 52:121-126, 1992
6. Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H: Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 14:131-136, 2004 (Pubitemid 38656384)
7. Bleehen NM, Stenning SP: A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 64:769-774, 1991
8. Brady LW: A new treatment for high grade gliomas of the brain. Bull Mem Acad R Med Belg 153:255-262, 1998
9. Brady LW, Markoe AM, Woo DV, Amendola BE, Karlsson UL, Rackover MA, et al: Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. A pilot study. Front Radiat Ther Oncol 24:151-165, 1990
10. Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, et al: Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24:3871-3879, 2006
11. Butowski N, Prados MD, Lamborn KR, Larson DA, Sneed PK, Wara WM, et al: A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys 61:1454-1459, 2005 (Pubitemid 40470428)
12. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, et al: A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65:1422-1428, 2006 (Pubitemid 44425201)
13. Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, et al: Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60:353-357, 2004 (Pubitemid 39233451)
14. Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, et al: Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys 66:818-824, 2006 (Pubitemid 44436691)
15. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-710, 1993 (Pubitemid 23133591)
16. Dadparvar S, Krishna L, Miyamoto C, Brady LW, Brown SJ, Bender H, et al: Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. Cancer 73 (3 Suppl): 884-889, 1994 (Pubitemid 24046645)
17. Del Rowe J, Scott C, Werner-Wasik M, Bahary JP, Curran WJ, Urtasun RC, et al: Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 18:1254-1259, 2000 (Pubitemid 30159843)
18. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC: Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus 20(4):E1, 2006
19. Derui L, Woo DV, Emrich J, Steplewski Z, Rodeck U, Herlyn D, et al: Radiotoxicity of 125I-labeled monoclonal antibody 425 against cancer cells containing epidermal growth factor receptor. Am J Clin Oncol 15:288-294, 1992
20. DeVita VT, Hellman S, Rosenberg SA: Cancer: Principles and Practice of Oncology, ed 7. Philadelphia: Lippincott Williams & Wilkins, 2005
21. Emrich JG, Brady LW, Quang TS, Class R, Miyamoto C, Black P, et al: Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol 25:541-546, 2002 (Pubitemid 35453655)
22. Emrich JG, Hand CM, Dilling TJ, Class R, Bender H, Brady LW: Biodistribution of 125I-MAb 425 in a human glioma xenograft model: effect of chloroquine. Hybridoma 16:93-100, 1997 (Pubitemid 27148696)
23. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993 (Pubitemid 23100496)
24. Fisher B, Won M, Macdonald D, Johnson DW, Roa W: Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 53:980-986, 2002 (Pubitemid 34722645)
25. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
26. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, et al: Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21:1485-1491, 2003
27. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al: Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462-1466, 2005 (Pubitemid 40315227)
28. Hess KR: Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 42:227-231, 1999
29. Klautke G, Schütze M, Bombor I, Benecke R, Piek J, Fietkau R: Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme. J Neurooncol 77:199-205, 2006
30. Kleinberg L, Grossman SA, Carson K, Lesser G, O'Neill A, Pearlman J, et al: Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J Clin Oncol 20:3149-3155, 2002
31. Langer CJ, Ruffer J, Rhodes H, Paulus R, Murray K, Movsas B, et al: Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:113-119, 2001
32. Laperriere NJ, Leung PM, McKenzie S, Milosevic M, Wong S, Glen J, et al: Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 41:1005-1011, 1998
33. Laterra JJ, Grossman SA, Carson KA, Lesser GJ, Hochberg FH, Gilbert MR: Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro Oncol 6:15-20, 2004
34. Li B, Chang CM, Yuan M, McKenna WG, Shu HK: Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63:7443-7450, 2003
35. McDermott MW, Berger MS, Kunwar S, Parsa AT, Sneed PK, Larson DA: Stereotactic radiosurgery and interstitial brachytherapy for glial neoplasms. J Neurooncol 69:83-100, 2004
36. Mikkelsen T, Lush R, Grossman SA, Carson KA, Fisher JD, Alavi JB, et al: Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Invest New Drugs 25:259-263, 2007
37. National Cancer Institute: Common terminology criteria for adverse events (CTCAE) and common toxicity criteria (CTC). (http://ctep.cancer.gov/ protocolDevelopment/electronic- applications/ctc.htm) [Accessed March 8, 2010]
38. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R: Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12:7261-7270, 2006
39. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al: Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25:2288-2294, 2007
40. Puchner MJ, Herrmann HD, Berger J, Cristante L: Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients. J Neurooncol 49: 147-155, 2000
41. Quang TS, Brady LW: Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 58:972-975, 2004
42. Salacinski PR, McLean C, Sykes JE, Clement-Jones VV, Lowry PJ: Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3α,6α- diphenyl glycoluril (Iodogen). Anal Biochem 117:136-146, 1981
43. Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, et al: The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51:343-357, 2002
44. Snelling L, Miyamoto CT, Bender H, Brady LW, Steplewski Z, Class R, et al: Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma 14:111-114, 1995
45. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner- Wasik M, Lustig R, et al: Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60:853-860, 2004
46. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018, 2002
47. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ: Fluorescence-guided surgery with 5-aminole-vulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392-401, 2006
48. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
49. Vuorinen V, Hinkka S, Färkkilä M, Jääskeläinen J: Debulk ing or biopsy of malignant glioma in elderly people-a randomised study. Acta Neurochir (Wien) 145:5-10, 2003
50. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333-343, 1978
51. Walker MD, Strike TA, Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725-1731, 1979
52. Werner-Wasik M, Scott CB, Nelson DF, Gaspar LE, Murray KJ, Fischbach JA, et al: Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer 77:1535-1543, 1996
53. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5: 79-88, 2003
54. Woo DV, Li DR, Brady LW, Emrich J, Mattis J, Steplewski Z: Auger electron damage induced by radioiodinated iodine-125 monoclonal antibodies. Front Radiat Ther Oncol 24:47-68, 1990